Macrophages adhering to the surface of larvae of the nematode parasite Heligmosomoides polygyrus bakeri (Hpb). The macrophages react to immune regulatory products of the larvae (e.g. the protein Hpb glutamate dehydrogenase) by switching on the transcription factor hypoxia-inducible factor 1-alpha (green) and the enzyme cyclooxygenase-2 (red).© Dr. Julia Esser-von Bieren, edited with the help of Dr. Arndt von Bieren

German researchers have isolated a substance from parasitic roundworm larvae to alleviate inflammation and treat asthma in a rodent model.

Photo: Erich Westendarp auf Pixabay

Last year, the biotechnology sector in Switzerland has continued its growth and proved to be a magnet for fresh capital and investment. This is revealed by the Swiss Biotech Report 2020.

Model of SARS-CoV-2. © CDC

Up to today, Novartis and Bayer announced donations of several millions of old antimalaria pills based on anecdotical reports of efficacy in COVID-19 patients. Now Novartis has started a study.

The vaccine candidate targets the SARS-CoV-2 spike protein. © University of Oxford

Dutch Halix BV will manufacture a ChAdOx1 nCoV-19 vaccine, developed at the University of Oxford .

© Carbios

For years, French Carbios SAS has worked to set up a process that effectively depolymerizes PET, one of the most common plastics. Now its process has been published.

Amplidiag Easy, developed in partnership with Tecan, automates the nucleic acid extraction and PCR plate setup for all Amplidiag diagnostic products. © Mobidiag/Tecan

Molecular diagnostics specialist Mobidiag Ltd has got emergency approval for its Amplidiag® COVID-19 molecular diagnostic test in Finland.

Part of the phylogenetic tree published in PNAS. https://www.pnas.org/content/early/2020/04/07/2004999117. © Proc. Natl. Acad. Sci. USA

British researchers have tabled a phylogenetic tree showing different subtypes of SARS-CoV-2 developed in Asia, Europe and the US.

Lady with solnatide vials in production. © Apeptico

Austrian COVID-19 patients with severe lung dysfunction for the first time have a treatment option within a compassionate use program for Apeptico’s solnatide.

© Cytiva/GE Healthcare Life Sciences
Following the completion of Danaher’s €19.5bn take-over of GE Healthcare Life Sciences, GE’s CDMO arm is renamed Cytiva.
Pixabay.com/VSRao

Low intrinsic efficacy can explain the reduced side effects of new agonists of the m-opioid receptor a British-Australian reseach team reports.